- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06306755
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer (ERSS-EGC)
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer: A Community-Based Randomized Controlled Trial
To evaluate the feasibility, applicability, effectiveness, and health-economic value of the risk-based sequential screening modality for esophageal and gastric cancers, the investigators aim to initiate a community-based randomized controlled trial in Xun County, Henan Province, which is a high-risk region of upper gastrointestinal cancer (UGIC) in northern China.
A total of 258 target villages from all the 11 communities (townships and streets) in Xun County will be randomly selected and assigned to the sequential screening group and the universal screening group at a ratio of 2:1 and the total sample size will be 21,000.
In the sequential screening group, participants in the top 50% risk level (i.e., stratified as the high-risk subgroup) will be offered a standard upper gastrointestinal endoscopic screening. In contrast, all participants in the universal screening group will receive the endoscopic examination. The surveillance strategy for participants with screening-detected premalignant lesions in the sequential screening group will be tailored based on individualized risk assessment using endoscopic characteristics, pathological diagnosis, and biomarkers. Surveillance for participants in the universal screening group will adhere to current guidelines for UGIC screening and clinical treatment.
Detection rates of upper gastrointestinal malignant lesions, early-stage malignant lesions and premalignant lesions, and health-economic indicators such as the unit cost per detected malignant lesions will be compared between the two groups.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A series of challenges have arisen for the current UGIC screening modality in China, including high screening costs, low detection rates, delayed and unstandardized treatment, and lack of sustainability and scalability. These challenges significantly hinder the normalization and high-quality implementation of UGIC prevention and control efforts. The precision shift in the screening modality is expected to result in substantial savings in medical resources while maximizing the identification and management of high-risk populations.
The investigators aim to initiate a community-based randomized controlled trial to evaluate the effectiveness of risk-based sequential screening for esophageal and gastric cancer (ERSS-EGC trial) in Xun County of Henan Province, which is a high-risk region of UGIC in northern China.
According to the baseline data obtained from our prior UGIC screening program conducted in the same region (He et al., Gut, 2019), the detection rate of upper gastrointestinal malignant lesions in the targeted population (aged 50-69 years) in the universal screening group is estimated to be 1.1%. It is assumed that the implementation of sequential screening will increase this detection rate by 70%, indicating an expected detection rate of 1.9% for upper gastrointestinal malignant lesions in the sequential screening group. Ultimately, a total of 7,674 endoscopies (with 3,837 in each group) will be required to achieve a statistical power of 80% at a one-sided significance level of 2.5%.
Based on the estimated population coverage determined by sample size, a total of 258 target villages from all the 11 communities (townships and streets) in Xun County will be randomly selected, stratified by townships and streets. These 258 target villages will be randomly assigned to either the sequential screening group or the universal screening group at a ratio of 2:1, based on the population size of each village and stratified by region (urban and rural areas). This results in 172 villages in the sequential screening group and 86 villages in the universal screening group. Approximately 21,000 permanent residents aged 50 to 69 residing in the target villages will be enrolled in the trial.
All enrolled eligible participants will receive an epidemiological questionnaire investigation (collecting data on basic information, dietary habits, environmental exposure, family history, symptoms, quality of life, etc.), and a physical examination.
In the sequential screening group, all enrolled participants will be offered a risk assessment for esophageal and gastric malignancies based on two questionnaire-based diagnostic models (Liu et al., Cancers, 2022, 14(23):5945; Zheng et al., Chin Med J (Engl), 2024). Participants identified as "high-risk" (i.e., with a top 50% risk level) for esophageal and/or gastric malignancy will receive the standard upper gastrointestinal endoscopy. Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them. For participants with screening-detected premalignant lesions, the risk of progression will be evaluated based on endoscopic characteristics, pathological diagnosis, and biomarkers. Individualized reexamination and surveillance will be implemented accordingly.
In the universal screening group, all enrolled participants will receive the same standard upper gastrointestinal endoscopy as those in the sequential screening group, irrespective of the results of the risk assessment. Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them. For participants with screening-detected premalignant lesions, the reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment.
The primary outcome of this study is the detection rate of upper gastrointestinal (esophageal/gastric) malignant lesions. The secondary outcomes include the rate of early-stage upper gastrointestinal (esophageal/gastric) malignant lesions, detection rate of upper gastrointestinal (esophageal/gastric) premalignant lesions, response rate of endoscopic examination, total screening costs, unit cost per detected upper gastrointestinal malignant lesions, unit cost per detected early-stage upper gastrointestinal malignant lesions, unit cost per detected upper gastrointestinal premalignant lesions, satisfaction of project executors and participants, rate of timely treatment, UGIC-specific mortality, all-cause mortality, and quality of life.
Through a comprehensive comparison with the universal screening, this trial will provide high-level evidence regarding the feasibility, applicability, effectiveness, and health-economic value of the sequential screening modality. Furthermore, it could effectively facilitate standardized diagnosis and treatment for screening-detected patients, providing crucial practical experience and scientific evidence for the reform and development of secondary prevention strategies for UGIC in China.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zhonghu He
- Phone Number: 010-88196702
- Email: zhonghuhe@bjcancer.org
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Department of genetics, Peking University Cancer Hospital & Institute
-
Contact:
- Zhonghu He
- Email: zhonghuhe@bjcancer.org
-
Principal Investigator:
- Zhonghu He, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Permanent residency in the target villages in Xun County, Henan Province, China;
- Aged 50 to 69 at the enrollment;
- Voluntarily participate in this study and provide informed consent.
Exclusion Criteria:
- Had a history of endoscopic examination within 5 years prior to the initial interview;
- Had a history of cancer;
- Had a history of mental disorder;
- Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV);
- Had severe cardiovascular and cerebrovascular diseases;
- Had severe respiratory disease, dyspnea, or asthmaticus status;
- Had retropharyngeal abscess, severe spinal deformity, or aortic aneurysm;
- With physical debility unable to tolerate endoscopic examination, or with difficulty in achieving sedation and self-control;
- In the acute phase of corrosive inflammation of the upper gastrointestinal tract, or with suspected perforation of the upper gastrointestinal tract;
- Had massive ascites, severe abdominal distension, or severe esophageal varices;
- Pregnancy;
- Had severe history of allergies;
- Had propensity for bleeding (coagulopathy);
- Others unable to tolerate the clinical examinations involved in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequential screening group
The enrolled participants will undergo a questionnaire investigation and receive a risk assessment for esophageal and gastric malignancies based on two questionnaire-based diagnostic models.
Participants identified as "high-risk" (i.e., with a top 50% risk level) for esophageal and/or gastric malignancy will receive the standard upper gastrointestinal endoscopy.
Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them.
For participants with screening-detected premalignant lesions, the risk of progression will be evaluated based on endoscopic characteristics, pathological diagnosis, and biomarkers.
Individualized reexamination and surveillance will be implemented accordingly.
|
|
Active Comparator: Universal screening group
The enrolled participants will undergo a questionnaire investigation and receive the same standard upper gastrointestinal endoscopy as those in the sequential screening group, irrespective of the results of the risk assessment.
Standardized diagnosis and treatment recommendations will be provided to patients with screening-detected malignant lesions, and green referral channels will be established for them.
For participants with screening-detected premalignant lesions, the reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection rate of upper gastrointestinal (esophageal/gastric) malignant lesions
Time Frame: 12 months
|
Number of detected malignant lesions / Number of completed endoscopies × 100%
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of early-stage upper gastrointestinal (esophageal/gastric) malignant lesions
Time Frame: 12 months
|
12 months
|
|
Detection rate of upper gastrointestinal (esophageal/gastric) premalignant lesions
Time Frame: 12 months
|
12 months
|
|
Response rate of endoscopic examination
Time Frame: 12 months
|
12 months
|
|
Total screening costs
Time Frame: 12 months
|
12 months
|
|
Unit cost per detected upper gastrointestinal (esophageal/gastric) malignant lesions
Time Frame: 12 months
|
12 months
|
|
Unit cost per detected early-stage upper gastrointestinal (esophageal/gastric) malignant lesions
Time Frame: 12 months
|
12 months
|
|
Unit cost per detected upper gastrointestinal (esophageal/gastric) premalignant lesions
Time Frame: 12 months
|
12 months
|
|
Satisfaction with the risk-based sequential screening modality
Time Frame: 12 months
|
Satisfaction with the risk-based sequential screening modality is measured through a one-on-one interview using a semi-structured questionnaire specially designed for this trial.
|
12 months
|
Rate of timely treatment
Time Frame: 12 months
|
12 months
|
|
UGIC-specific mortality
Time Frame: 5-10 years
|
5-10 years
|
|
All-cause mortality
Time Frame: 5-10 years
|
5-10 years
|
|
Quality of life Scale Score
Time Frame: 12 months
|
European Quality of Life 5-Dimension (EQ-5D) index score is used to assess health-related quality of life.
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021YFC2500405
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Risk Assessment and Individualized Surveillance
-
University of IbadanUniversity College Hospital, Ibadan; Obafemi Awolowo University Teaching Hospital and other collaboratorsCompletedBreast Cancer | Health Behavior | Health Knowledge, Attitudes, Practice | Health Care Utilization | Risk Reduction BehaviorNigeria
-
University of Wisconsin, MadisonWithdrawn
-
Karolinska University HospitalUnknownBreast Cancer | Cardiomyopathies | CardiotoxicitySweden
-
University of TorontoCompletedHypertension | Diabetes | Hyperlipidemia | Cardiovascular Risk FactorsCanada
-
Oslo University HospitalUniversity of Oslo; Rigshospitalet, Denmark; University of Oxford; Norwegian SIDS... and other collaboratorsEnrolling by invitationPreeclampsia | High Risk Pregnancy | Hypertensive Disorder of Pregnancy | Premature Preterm Rupture of Membranes | Previous Adverse Obstetric OutcomeNorway
-
Ann & Robert H Lurie Children's Hospital of ChicagoTerminated
-
McGill University Health Centre/Research Institute...Jewish General HospitalCompletedGenital Neoplasms, Female | LymphedemaCanada
-
National Center for AIDS/STD Control and Prevention...UnknownUsing HIV Risk Assessment Tool to Promote HIV Testing Among Men Who Have Sex With Men (online-RASSL)HIV Infections | HIV/AIDS | Social MediaChina
-
Magdi Yacoub Heart FoundationRecruiting
-
Eunice Kennedy Shriver National Institute of Child...Completed